Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Saturday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright decreased their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th.

Oncternal Therapeutics Stock Performance

NASDAQ ONCT opened at $4.11 on Friday. Oncternal Therapeutics has a 1-year low of $3.25 and a 1-year high of $13.14. The company has a market capitalization of $12.17 million, a price-to-earnings ratio of -0.33 and a beta of 1.36. The stock’s 50 day moving average is $6.13 and its two-hundred day moving average is $7.85.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. The company had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. During the same quarter in the previous year, the company posted ($3.00) earnings per share. On average, analysts predict that Oncternal Therapeutics will post -11.63 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC acquired a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. 16.05% of the stock is owned by institutional investors and hedge funds.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.